SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-24-019511
Filing Date
2024-05-15
Accepted
2024-05-15 08:25:42
Documents
16
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 150147
2 ex31-3.htm EX-31.3 11013
3 ex31-4.htm EX-31.4 11168
4 ex97-1.htm EX-97.1 34099
  Complete submission text file 0001493152-24-019511.txt   455750

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20231231.xsd EX-101.SCH 3012
6 XBRL LABEL FILE zvsa-20231231_lab.xml EX-101.LAB 36884
7 XBRL PRESENTATION FILE zvsa-20231231_pre.xml EX-101.PRE 24144
19 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 7761
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-41184 | Film No.: 24947317
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)